Facebook
Twitter
LinkedIn
ForwardManagement of Toxicities with Targeted Therapies for Breast Cancer
The decision-making process for metastatic breast cancer should involve a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies. With expanding treatment options, it is difficult for clinicians to remain current on important criteria used in choosing optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Also, the new therapies (CDK 4/6 inhibitors, PARP inhibitors, PI3KCA inhibitor, and PD-L1 inhibitor) all have different mechanisms of action and different toxicity profiles. Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with breast cancer.
Learning Objectives
Following this program, participants should be able to:
- Review the mechanism of action of currently available targeted therapies.
- Review safety profiles of targeted agents used in metastatic breast cancer.
- Optimally manage drug interactions and common toxicities related to targeted agents.
Chau Dang, MD
Memorial Sloan Kettering Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Chau Dang, MD
Daiichi-Sankyo Co.: Scientific Advisor
Lilly USA: Scientific Advisor
PUMA: Scientific Advisor; Grant/Research Support
Roche Laboratories, Inc.: Scientific Advisor/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina A. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer Burns; Susan D. Darlow, PhD; Mary A. Dwyer, MS; Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.25 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.25 contact hours (0.025 CEUs) of continuing education credit. UAN: JA4008196-0000-20-034-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 3/15/2021. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.25 AAPA Category 1 CME credit
- 0.25 ACPE contact hours
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC contact hours
- 0.25 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing